INTRODUCTION

The most prevalent source of cancer-associated mortality worldwide is lung cancer, and the most common histological type is lung adenocarcinoma (LUAD), accounting for approximately half of the cases.\(^1\)\(^{-3}\) LUAD is associated with high degree of malignancy and a poor prognosis.\(^4\)\(^,\)\(^5\) The therapy for LUAD is based on the grade and stage, which is primarily defined by the assessment of tumor histology and patient characteristics by pathologists.\(^6\)

Evidence has been emerging of the importance of long non-coding RNAs (lncRNAs) in genome instability. However, no study has established how to classify such lncRNAs linked to genomic instability, and whether that connection poses a therapeutic significance. Here, we established a computational frame derived from mutator hypothesis by combining profiles of lncRNA expression and those of somatic mutations in a tumor genome, and identified 185 candidate lncRNAs associated with genomic instability in lung adenocarcinoma (LUAD). Through further studies, we established a six lncRNA-based signature, which assigned patients to the high- and low-risk groups with different prognosis. Further validation of this signature was performed in a number of separate cohorts of LUAD patients. In addition, the signature was found closely linked to genomic mutation rates in patients, indicating it could be a useful way to quantify genomic instability. In summary, this research offered a novel method by through which more studies may explore the function of lncRNAs and presented a possible new way for detecting biomarkers associated with genomic instability in cancers.

KEYWORDS

genome instability, long non-coding RNAs, lung adenocarcinoma, mutator phenotype
Clinical features of patients (such as age, gender, stage, etc.) are currently commonly used prognostic factors of LUAD. However, it is acknowledged that LUAD is a complex disease characterized by genetic, clinical, and pathological heterogeneity. For example, LUAD shows molecular characteristics that vary according to the patients’ smoking history. Therefore, to better determine the clinical results of patients with LUAD, better prognostic biomarkers are needed.

Genomic instability has shown to be a marker of prognosis, and it is correlated with tumor proliferation and survival. It has been proposed that the molecular foundation of genomic instability remains unclear. Also, abnormal transcripational and post-transcripational activities have been reported linked to genomic instability, which indicates the possibility of a molecular signature to serve as the quantitative indicator of genomic instability. In fact, Bao et al. examined specimens of breast cancer and found 128 novel long non-coding RNAs (lncRNAs) that were correlated with genomic instability. The Wang’s study established a 10-miRNA-based signature related to genomic instability in ovarian cancer. LncRNAs are transcripts that are greater than 200 nucleotides that do not have coding ability. Numerous studies over the past few years have shown that lncRNAs play a role in various biological functions, especially that the abnormal expressions of lncRNAs may have a significant impact on cancer progression, including proliferation, migration, invasion and cancer metastasis. Several lncRNAs have been found expressed in tumor tissues, such as MALAT1 and H19. The utilization of next-generation sequencing technologies to examine expression profiles of a significant number of lncRNAs has opened new possibilities for the assessment of the role of lncRNAs. Recent literature has shown that IncRNAs perform crucial roles in the preservation of genomic instability. A recent research has shown a particular lncRNA, NORAD, contributing to genomic stability by interacting with proteins involved in the process of DNA replication and repair. CUPID1 and CUPID2, two human lncRNAs recently found by Betts et al., regulate the DNA repair-associated genes. Another lncRNA, named DDSR1, is thought to be essential in genomic instability through interacting with proteins involved in the process of DNA damage and controlling the expression levels of corresponding genes. Despite some lncRNAs have been found to participate in maintaining genomic stability, the therapeutic importance of them in cancer is still mainly unexplored.

In this research, to assess the possibility of lncRNA-based signature to serve as a predictor of genomic instability, we tried to build a computational frame derived from mutator hypothesis. The frame combined the profiles of lncRNA expression with those of somatic mutations in a tumor genome, thus enhancing its prognostic function.

## 2 MATERIALS AND METHODS

### 2.1 Information review

The details regarding clinical characteristics, RNA-seq expression, and somatic mutations data of LUAD samples were obtained from the database online, which is called The Cancer Genome Atlas (TCGA). The lncRNA expression details is collected from the TANRIC database. For further analysis, 490 samples were retained, including survival details, somatic mutation information, lncRNA and mRNA expression information, and typical clinical features. All of the patients with LUAD used were assigned into two sets. The set named the training set consisted of 246 patients, and was used to define the lncRNA-based signature with prognostic value and develop the prognostic risk model. The other set named testing set consisted of 244 patients and was used to objectively verify the efficacy of the signature. The predictive value of the prognostic signature was further investigated in the whole TCGA set. Other three separate LUAD sets named GSE68465, GSE10072 and GSE30219 were acquired from another database (the Gene Expression Omnibus, GEO) for further confirmation. The clinical and pathological characteristics of LUAD patients in the TCGA database were briefly addressed in Table 1.

### 2.2 Detection of genomic instability-associated lncRNAs

After combining somatic mutation profiles and lncRNA expression profiles in a tumor genome, a computational frame derived from mutator hypothesis was used to classify genome instability-associated lncRNAs. The frame was listed in Figure 1: (a) the total number of somatic mutations was calculated; (b) LUAD patients in the training set were listed in a decreasing order according to their somatic cumulative mutations; (c) the last quarter of patients in the training set were assigned into the genomic stable-like group (GS-like group), while the top quarter of them were assigned into the genomic unstable-like group (GU-like group); (d) Comparison of the lncRNAs’ expression profiles between the two groups was performed with significance analysis of microarrays (SAM) method; (e) lncRNAs differentially expressed in two groups were considered to be genomic instability-associated lncRNAs (GILncRNAs).
2.3 | Statistical analysis

Ward’s linkage method and Euclidean distances method were used to conduct hierarchical cluster research, by which LUAD patients in the training set from TCGA were separated into two clusters, the GU-like cluster and the GS-like cluster with different somatic mutation counts. For constructing the prognostic signature from the 185 genomic instability-associated lncRNAs, univariate Cox regression analysis was carried out in the training set to screen the genomic instability-associated lncRNAs, whose expression levels were closely associated with overall survival (OS). Then, the lncRNAs, whose Cox P-value were smaller than 0.05, were considered as hub ones with prognostic value, and were included in the multivariate Cox regression analysis. The variables with p-value <0.05 in the multivariate Cox analysis were chosen as the optimal ones to construct the signature. Finally, on the basis of the coefficients from the multivariate regression analysis and the expression levels of those optimal lncRNAs with prognostic value, we built a genome instability-derived lncRNA signature (GILncSig) for predicting the clinical outcome of LUAD patients. The GILncSig was as followed:

$$\text{GILncSig (patient)} = \sum_{i=1}^{n} \text{coef(lncRNAi)} \times \text{expr(lncRNAi)}.$$ 

In LUAD, the score of GILncSig represented the prognostic risk level of patients. In this signature, lncRNAi means the ith prognostic lncRNA. Coef(lncRNAi) referred to the coefficient of multivariate Cox regression analysis, which represented the lncRNAi’s contribution to prognostic risk scores. And the expr(lncRNAi) represents the lncRNAi’s expression level. In the training set, we used the median score of LUAD patients to be a risk cutoff, which classified the patients into the low-group or high-risk group according to their GILncSig scores.

Kaplan–Meier method was carried out to assess the survival rate for the two groups with different prognostic risks. Using the log-rank test, the difference in survival between the two risk groups with a meaningful amount of 5 percent was calculated. Multivariate Cox regression analysis and stratified analysis were carried out to evaluate the association between the GILncSig scores and other clinical features. Hazard ratios (HRs) were calculated using Cox analysis. The receiver operating characteristic (ROC) curve dependent on time was also used to evaluate the prognostic performance of the GILncSig. Statistical analyses were carried out with R-software 4.0.3.32

2.4 | Functional enrichment analysis

We measured the relationship between the expression of lncRNAs and paired mRNAs using Pearson correlation method. The top ten mRNAs were then classified
as the co-expressed partners of corresponding lncRNAs. Functional enrichment analyses of those co-expressed partners were performed to identify the markedly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) terms to further predict the lncRNAs’ potential functions. The functional enrichment analysis was conducted in R-version 4.0.3 using clusterProfiler tools. The Gene Set Enrichment Analysis (GSEA) was also carried out to further investigate the function of this genomic instability lncRNA-based signature, including its molecular function and gene-gene network. GSEA was performed on the basis of the while TCGA set, where 1000 random sample permutations were carried out, with a significance threshold of FDR <0.1 and \( p < 0.05 \).

3 | RESULTS

3.1 | Identification of genomic instability-related lncRNAs (GILncRNAs) in LUAD patients

In order to classify lncRNAs which might be closely linked to genomic instability, we estimated the total count of somatic mutations in each LUAD patient. The numbers were then sorted by declining order. Then, the last quarter of patients (\( n = 139 \)) and the top quarter of patients (\( n = 134 \)) were selected as the GS-like group and GU-like group separately. Comparison of the expression profiles of lncRNAs between the two groups was conducted to classify which lncRNAs were significantly distinct. Through SAM method, 185 lncRNAs were then identified, whose expression levels were significantly different. The fold change value of these lncRNAs was less than −1.0 or greater than 1.0, and the \( p \)-value adjusted by FDR was less than 0.05. Among them, 80lncRNAs were found upregulated in GU-like group, while other 105 ones were downregulated (Table S1). Analysis of hierarchical clustering was carried out on the LUAD samples from the TCGA database using the lncRNAs extracted from the analysis of genes differentially expressed between groups. Samples were separated into two groups based on the expression of 185 selected lncRNAs (Figure 2A). In the two groups, the pattern of somatic mutation was markedly different. The group that had higher somatic mutations count was designated as the GU-like group, while the other group was designated as the GS-like group. The median level of somatic mutations was substantially higher in the GU-like group than in the GS-like group (\( p < 0.001 \), U test; Figure 2B). By comparing the expression levels of the UBQLN4 between the two groups, we found that the expression level of UBQLN4 was far higher in the GU-like group than in the GS-like group (\( p < 0.001 \), Mann–Whitney \( U \) test).

Functional enrichment review was conducted to decide which functions any of the 185 lncRNAs might have, and determine whether their functions were correlated with genomic instability. We quantified the relationship between the 185 lncRNAs and protein-coding genes (PCGs), and picked the top 10 PCGs that displayed the highest correlation with each lncRNA. We built a set of RNA-mRNA co-expression network, the nodes in which represented lncRNA and mRNAs. As shown in Figure 2D, the lncRNA and mRNA were connected if they were related to each other. In light of GO analysis shown in Figure 2E, mRNAs involved in this co-expression network had a close relationship with the creation of genomic instability, since they were linked to DNA binding transcription activator activity, and actin binding and RNA polymerase II-specific DNA-binding transcription activator activity. KEGG pathway studies on PCGs correlated with lncRNAs also revealed 30 substantially enriched pathways, several main pathways of which are correlated with genomic instability, like DNA replication, nucleobase-containing small molecule interconversion and DNA-dependent DNA replication.
3.2 Development of GILncSig for predicting the clinical outcome in training set

All of those 490 TCGA patients with LUAD were randomly separated into two sets, named the training set \((n = 246)\) and the testing set \((n = 244)\), to explore the prognostic roles of these GILncRNAs. To classify prognostic-related lncRNA, we assessed the association between lncRNAs expression levels and OS using Cox regression analysis in the training sample. There were ten hub candidate GILncRNAs in the analysis, and they showed a closely correlation with the outcomes of LUAD patients \((p < 0.05; \text{Table 2})\). Multivariate Cox proportional hazard regression analysis was then carried out among the ten candidate lncRNAs and common clinical features (such as age, sex, and stage) to decide if those candidate lncRNAs could serve as independent prognostic factors. Finally,
six of ten selected lncRNAs (RHOXF1-AS1, PLAC4, LINC01116, AC099850.4, LINC01671 and FAM83A-AS1) endured the multivariate checking for significance and preserved their prognostic significance (Table S2). Based on expression levels of six GILncRNAs, a GILncSig score was established to accurately evaluate the risk of LUAD patients as follow: GILncSig score = (−0.2206 × expression level of RHOXF1-AS1) + (0.0266 × expression level of PLAC4) + (0.1233 × expression level of LINC01116) + (0.0473 × expression level of AC099850.4) + (0.0558 × expression level of LINC01671) + (0.0316 × expression level of FAM83A-AS1).

The coefficients of lncRNA PLAC4, LINC01116, AC099850.4, LINC01671 and FAM83A-AS1 were positive in the GILncSig, suggesting that they may be risky factors since their high expressions were linked to bad prognoses. Meanwhile, lncRNA RHOXF1-AS1 had a beneficial effect since the high expression of it was linked to longer survival. Based on the signature associated with genomic instability, we measured each patient's risk score, the median one of which was utilized to evaluate the cutoff scores for dividing the LUAD patients into two separate prognostic classes. Patients whose scores are higher than or equivalent to the cut-off were deemed high-risk, while the majority of patients were categorized as low-risk. There was a marked difference in the survival rates between patients of the two risk groups (p < 0.001, log-rank test). The low-risk group at 3 years had a survival rate of 27.6%, much higher than that of the high-risk group (22.8%; Figure 3A). The 3-year area under curve (AUC) built from the time-dependent ROC curve in the training set was approximately 0.763 (Figure 3B). UBQLN4 (Ubiquilin 4) is a regulator of protein degradation,33 and it mediates the proteasome targeting of misfolded or mislocated proteins.34 UBQLN4 is also reported as a key regulator that inhibits homologous recombination repair, thereby promoting genomic instability.35,36

The patients were sorted according to their ranking, to observe how the expression of UBQLN4, the total count of somatic mutations and the level of the lncRNAs involved in the GILncSig shift together with the rise of the score (Figure 3C). In patients with poorer scores, the expression levels of AC099850.4, LINC01116, PLAC4, LINC01671 and FAM83A-AS1 were also low, whereas the expression for RHOXF1-AS1 was relatively high. However, in the patients with higher scores, the expression levels of the six lncRNAs displayed opposite performances. The findings of the comparison of UBQLN4 expression and somatic mutation analysis revealed significantly difference between the two groups. The count of somatic mutations in LUAD patients was notably lower in the low-risk group than in the other risk group (p < 0.001, U test; Figure 3D). Also, Figure 3E also revealed that the expression level of UBQLN4 was meaningfully lower in the group with low risk than in the group with high risk (p = 0.009, Mann–Whitney U test).

### 3.3 Further validation of GILncSig in the testing set and the TCGA set

We applied the GILncSig to the other separate testing set with 244 patients and checked the precision of its predictive potential. When the same GILncSig and corresponding cutoff were added to the testing set, the patients with LUAD were divided into the high-risk group and the low-risk group, which demonstrated distinctly different OS. The OS of samples was statistically higher in the low-risk group than in the other risk group (p = 0.045, log-rank test; Figure 4A). Additionally, 3-year survival rate was at 30.8 percent in the low-risk group, while it was much slower as 25.6 percent in the group with high risk. Figure 4B showed that the 3-year AUC calculation

| Ensembl ID       | Gene symbol | Genomic location          | HR  | 95% CI      | p-value |
|------------------|-------------|---------------------------|-----|-------------|---------|
| ENSG00000258545  | RHOXF1-AS1  | chrX:120,036,236-120,146,855 | 0.767 | 0.608–0.967 | 0.025   |
| ENSG00000273877  | AC236972.3  | chrX:153,225,649-153,230,357 | 0.715 | 0.516–0.989 | 0.0427  |
| ENSG00000280109  | PLAC4       | chr21:41,175,231-41,186,788 | 1.033 | 1.011–1.056 | 0.003   |
| ENSG00000163364  | LINC01116   | chr2:176,625,118-176,638,186 | 1.152 | 1.101–1.206 | <0.001  |
| ENSG00000265415  | AC099850.4  | chr17:59,202,677-59,203,829 | 1.064 | 1.026–1.103 | 0.001   |
| ENSG00000251026  | LINC02163   | chr5:104,079,847-104,406,121 | 1.234 | 1.010–1.508 | 0.039   |
| ENSG00000252431  | LINC01671   | chr21:42,579,759-42,615,095 | 1.039 | 1.011–1.068 | 0.005   |
| ENSG00000262454  | MIR193BH    | chr16:14,301,364-14,336,038 | 1.134 | 1.007–1.277 | 0.038   |
| ENSG00000232415  | ELN-AS1     | chr7:74,048,744-74,062,301  | 0.909 | 0.834–0.990 | 0.029   |
| ENSG00000204949  | FAM83A-AS1  | chr8:123,193,507-123,202,744 | 1.036 | 1.006–1.066 | 0.016   |
FIGURE 3 Identification of the lncRNA signature derived from genomic instability for predicting the LUAD patients' clinical outcomes. (A) Estimates of the LUAD patients' overall survival (OS) in the training set using the Kaplan-Meier method. All 246 LUAD patients in this set were assigned into the high-risk or the low-risk group. Univariate Cox analysis and the log-rank test were carried out to do the statistical analysis. (B) Analysis of the 3-year time-dependent ROC curves for the signature in the training set. (C) LncRNA expression patterns, somatic mutation number's distribution and the UBQLN4 expression's distribution along with the increase of the GILncSig scores. (D) Distribution of somatic mutations for LUAD patients in two risk groups. (E) Expression of UBQLN4 in both groups with different risks. Median values were reflected by horizontal lines. The Mann-Whitney $U$ test was carried out to analyze those statistics.
FIGURE 4 Evaluation of the GILncSig performance in the testing and the TCGA sets. (A) Estimates of OS by Kaplan-Meier in the testing set for low- or high-risk patients. (B) Analysis of ROC curves dependent on time and AUC for 3-year OS in the testing set for the GILncSig. (C) LncRNA expression patterns, somatic mutation number’s distribution and the UBQLN4 expression’s distribution for LUAD samples in the testing set. (D) Distribution of somatic mutations for patients with LUAD in two risk groups of the testing set. (E) UBQLN4 expression levels in the two groups with different risks. (F) Kaplan–Meier estimates of OS of two risk groups in the TCGA set. Analysis of statistics was carried out with univariate Cox regression and the log-rank test. (G) Analysis of ROC curves dependent on time and AUC for 3-year OS in the whole TCGA set. (H) LncRNA expression patterns, somatic mutation number’s distribution and the UBQLN4 expression’s distribution for samples in the TCGA set. (I) Distribution of somatic mutations in two risk groups of samples from the TCGA set. (J) UBQLN4 levels in the two groups in the TCGA set. Median values were reflected by the horizontal points. The Mann-Whitney U test was carried out to complete the statistical analysis.
in the testing set yields an overall performance of 0.663. The count of somatic mutation and the expression degree of UBQLN4 in the research sample is seen in Figure 4C. Further analysis revealed just like the identical findings in the training set above, the counts of somatic mutations were greatly different between the two risk groups of the testing set \( (p < 0.001, \text{Mann–Whitney U test; Figure 4D})\). Besides, Figure 4E showed that the UBQLN4 expression level was considerably lower in the low-risk group than in the high-risk group \( (p < 0.001, \text{Mann–Whitney U test})\).

In the TCGA set, all results obtained from the prognostic analysis of the GILncSig showed similar trend. All 490 patients with LUAD in the TCGA set were assigned to either the high-risk group or the low-risk group, which separately consisted of 244 and 246 samples. As shown in Figure S1, gene sets, activated in the high-risk group, we carried out GSEA analysis based on the TCGA set. As shown in Figure S1, gene sets, which were differentially enriched in the high-risk group of the TCGA database, were related to genomic instability, such as homologous recombination, cell cycle, mismatch repair, nucleotide excision repair (NER), RNA degradation and P53 signaling pathway.

3.4  Further confirmation for applying the IncRNA signature associated with genomic instability to three external LUAD data sets.

In order to verify the prognostic value of the GILncSig by applying it to other separate data sets from other platforms, the common microarray array was reannotated. We observed that only one IncRNA, PLAC4, in the six GILncRNAs was covered by GSE68465, GSE10072 and GSE30219, which had large sample sizes and common clinical features. Based on this, to further examine the relation between PLAC4 and LUAD or genomic instability, we explored the relation between the PLAC4 expression and UBQLN4 expression in these three independent data sets. Using Mann–Whitney test, the violin plots in Figure 5 indicated that the expression levels of UBQLN4 were considerably higher in patients with elevated PLAC4 than in those with low PLAC4 in the three GEO data sets (GSE68465 \( p < 0.001 \), GSE10072 \( p < 0.01 \) and GSE30219 \( p < 0.05 \)). These findings were close to the corresponding results found in the sets from the TCGA.

3.5  Comparison of efficiency in survival prediction between the GILncSig and existing IncRNA-dependent signatures in LUAD

To further validate the efficiency of the GILncSig in predicting the survival, two signatures based on IncRNAs reported recently were compared with GILncSig in the same TCGA LUAD patient cohort: 2- IncRNA signature derived from Yu’s research (YulncSig), and 5- IncRNA signature derived from Zeng’s study (ZenglncSig). It was obvious in Figure 6 that the GILncSig had an AUC value of 0.714 at three years, greater than that of the ZenglncSig (AUC = 0.643) and the YuLncSig (AUC = 0.689). We further performed the time-dependent ROC curves study of 3-year OS to compare the predictive efficiency among the GILncSig and two another IncRNA-based signature in LUAD. The four-IncRNA signature derived from Shukla’s research (ShuklaLncSig) was built based on the analyses of the RNA-Seq information from TCGA-LUAD. While, the six-IncRNA signature from Miao’s study was constructed by analyzing the immune infiltration-associated IncRNAs in LUAD patients. As shown in Figure S2, GILncSig had higher AUC value (AUC = 0.714) than that of the MiaoLncSig (AUC = 0.701) and the ShuklaLncSig (AUC = 0.682). The findings suggested the GILncSig had a good predictive performance.

3.6  Independence of the established GILncSig from clinical characteristics

Multivariate and Univariate Cox regression analyses were carried out on three common clinical characteristics and the prognostic risk score model, which was based on the GILncSig, to determine if the prognostic significance of GILncSig was independent of other typical clinical factors. As shown in Table 3, after adjusted for the three clinical features, the GILncSig showed a significant correlation
with the OS of samples in three sets from TCGA. It was notable in the multivariate Cox analysis that apart from the GILncSig, stage, one of the common clinical characteristics, was also observed significantly correlated to OS. While the distribution of age and gender showed no statistical difference ($p > 0.05$, Figure S3). To determine whether the GILncSig had an independent prognostic value from the stage, we stratified those LUAD patients obtained from the TCGA set by stage. Patients were also classified into two groups; one that was early-stage and one that was late-stage. There were 363 LUAD samples in stage I or II involved in the early-stage group, and the other 97 samples in stage III or IV were involved in the late-stage group. In early-stage group, the GILncSig was then applied to separate the 363 samples into two groups, including the high-risk group ($n = 167$) and the low-risk group ($n = 196$). Figure 7A showed that the OS was shorter in the high-risk group of the early-stage group than in the other group ($p < 0.001$, log-rank test). Similarly, patients in late-stage group were separated into low-risk and high-risk groups. Between the two groups, the OS was also obviously different ($p = 0.046$, log-rank test; Figure 7B). Thus, it was apparent that the GILncSig was an autonomous element of prognostic meaning and being correlated with OS. To further confirm the independence of GILncSig, we carried out survival analyses on patients with different stages. As shown in Figure S4, the OS of LUAD patients with high risk in stage I was significantly shorter, so was in high-risk patients in stage II ($p < 0.05$). However, the results of the OS analyses were not statistically significant ($p > 0.05$), which might be due to the small sample sizes.

4 | DISCUSSION

Many attempts have been made to investigate the incidence, growth, diagnosis and treatment of LUAD.41–44 Common histopathological features of stage, tumor size and Karnofsky Performance Status (KPS) are now still considered to be the most important prognostic factors in LUAD. Based on their pathological characteristics, LUAD patients are grouped into different groups to accept the corresponding care regimens.6,45–48 However, the clinical
performance of patients with LUAD remains somewhat heterogeneous owing to the shortcomings of typical histopathologic characteristics.49 Genomic instability has been reported in recent years as the pervasive hallmark of most cancers,50–52 and is also considered one of the prognostic factors of LUAD.53,54 During the development and recurrence of cancers, the diagnostic and prognostic implications of the genomic instability is non-ignorable.55 However, it is a major challenge for us to quantitatively measure the degree of genomic instability. Emerging data indicates that epigenetic and transcriptomic aberrations are closely related to genomic instability.56 The identification of PCGs and microRNAs linked to genomic instability has become a top priority. For the prediction of genomic instability, many efforts have also been made to develop miRNA or gene signature.55,57

LncRNAs have been considered an important part of tumor biology in recent years. The dysregulated expression of lncRNAs in cancer is associated with the progression of disease. So, they may be potential prognostic markers of cancer.58–60 Advances in the functional mechanism of lncRNAs make us realize that lncRNAs are also vital to maintaining genome stability, such as NORAD,61 H1962 and GUARDIN.63 For now, the identification of lncRNAs linked to genomic instability and the investigation of their clinical importance are in infancy. In this study, by combining the expression level of lncRNA and the tumor mutator phenotype, we built a frame to identify lncRNAs linked to genome instability. The total number of somatic mutations often represents the burden of mutations in tumors.64 It mainly includes a variety of somatic mutations, such as non-synonymous mutations, insertion/deletion mutations, and silent mutations.65 Experiments have confirmed that the total number of somatic mutations is closely related to clinicopathological characteristics,66 and often shows no change at relapse, meaning the number is stable.67 In addition, somatic mutations and the genomic instability caused by it may be an important driving factor for the development of chemotherapy resistance in malignant tumors.68 Hence, we used the total number of somatic mutations as the index for genomic instability.

Through combining the profiles of IncRNA expression with those of somatic mutation in LUAD, we finally found 185 novel IncRNAs linked to genomic instability. We further carried out functional enrichment analyses on genes co-expressed with the 185 IncRNAs. The results showed these genes enriched in the DNA replication and DNA-binding transcription activator activity. DNA replication occurs in all organisms and is the basis of biological genetics. The interference with DNA replication can lead to genomic instability,69,70 and DNA replication stress is a source of genomic instability, a distinct characteristic of cancer.71 An increasing number of studies have tried to understand the role of DNA-binding transcription activator activity in transcription-associated genome instability both in prokaryotes and in eukaryotes.72,73 These further confirmed that the 185 IncRNAs differentially expressed in two risk groups were linked to genome instability. The abnormal expression of these 185 IncRNAs might destroy the balance of the PCGs regulatory network to influence the usual gene damage repair pathway, which led to the disturbance of cellular genomic stability. Furthermore, we investigated

| Variables | Training set (n = 246) | Testing set (n = 244) | TCGA set (n = 490) |
|-----------|------------------------|----------------------|-------------------|
|           | Univariable model       | Multivariable model  |                   |
| GILncSig  |                        |                      |                   |
| High/low  | 1.037 1.019–1.055 <0.001 | 1.033 1.015–1.051 <0.001 |                   |
| Age       | 1.001 0.981–1.022 0.906  | 1.007 0.984–1.031 0.544  |                   |
| Gender    | 1.268 0.826–1.946 0.277  | 0.941 0.616–1.439 0.780  |                   |
| Stage     | 1.816 1.473–2.239 <0.001 | 1.500 1.238–1.817 <0.001 | 1.481 1.219–1.799 <0.001 |
|           | 1.005 0.989–1.020 0.553  | 1.029 1.019–1.039 <0.001 |                   |
| Gender    | 1.113 0.825–1.500 0.484  | 1.614 1.425–1.890 <0.001 |                   |
| Stage     | (III+IV)/(I+II)        | (III+IV)/(I+II)      | (III+IV)/(I+II)   |
|           | 1.005 0.989–1.020 0.553  | 1.641 1.425–1.890 <0.001 |                   |
|           | 1.026 1.016–1.036 <0.001 | 1.623 1.408–1.871 <0.001 |                   |
whether the outcomes of LUAD patients could be predicted by using these genomic instability-associated lncRNAs, and then established a GILncSig consisting of six lncRNAs related to genomic instability (RHOXF1-AS1, PLAC4, LINC01116, AC099850.4, LINC01671 and FAM83A-AS1). GILncSig divided LUAD samples in the training set into two risk groups, which had substantially different survival. It was also validated in the testing set and the entire TCGA set. The GSEA results revealed some pathways, such as homologous recombination, mismatch repair, nucleotide excision repair (NER) and RNA degradation, were highly enriched in the high-risk group. It has been reported that the role of homologous recombination in promoting genomic instability might contribute to the occurrence and development of tumors, hence homologous recombination should be tightly regulated in order to avoid genomic instability at mitosis. Mismatch repair often results in microsatellite instability, which is one of two main mechanisms of genomic instability, and tumor predisposition. NER, as one of four DNA repair systems, requires strict regulation to avoid genomic instability. The other gene enrichment pathways, such as RNA degradation, P53 signaling pathway and cell cycle, were also observed associated with genomic instability. Additionally, the GILncSig is strongly associated with the phenotype of the tumor mutator and the UBQLN4 expression level in LUAD, both of which are essential markers of genomic instability. Moreover, three external GEO data sets showed similar results. It was apparent that the expression level of PLAC4 was linked to that of UBQLN4 in LUAD patients (Figure 5). Up to now, there have been no studies of the biological roles of these lncRNAs involved in the GILncSig after a diligent literature search. However, we noticed that lncRNA; RHOXF1-AS1, located in chromosome Xq24, has
been found to be involved in the development of diseases caused by genetic variation.\textsuperscript{51} LINC01116 is located in 2q31 and known for promoting the development of cisplatin resistance in LUAD.\textsuperscript{82} FAM83A-AS1 is located in 8q24, whose high expression was recently found correlated positively with a poor prognosis of LUAD.\textsuperscript{83} LncRNA PLAC4 is located in chromosome 21q22 region, where SNP has been found involved in chromosomal aberration-related diseases.\textsuperscript{84} LINC01671 is located in 21q22 and AC099850.4 is located in Xq28, both of which have not been studied until now. The results of all this validation in different data sets and data collected from literature suggested that apart from owning a prognostic value, the specific GILncSig is also a genomic instability indicator for patients with LUAD, especially in the early stage LUAD.

Although our research provides valuable insights into the assessment of genomic instability and the prognosis of patients with LUAD, we note some major limitations. Firstly, there are some studies that have indicated the total number of somatic mutations may increase with age, so it might not be the optimal choice as the index for genomic instability. Secondly, the information of LUAD patients in GEO sets did not include somatic mutations, and the clinical information and the lncRNA expression data in the GEO sets was incomplete, where we only found the expression information of lncRNA PLAC4 involved in the signature. Hence, more separate data sets with somatic mutations, more complete the lncRNA expression data and clinical characteristics are needed to further verify the prognostic value of the GILncSig. In addition, the GILncSig was actually built basing on our computational frame derived from mutator hypothesis; thus, more practical studies are needed for experimental biologists to explore the GILncSig’s regulatory mechanisms in the maintain of genomic instability.

\section{CONCLUSION}

This research suggested a computational frame derived from the mutator hypothesis to classify lncRNAs associated with genomic instability, which offers a crucial approach for investigating functions of lncRNAs in genomic instability. We developed a GILncSig as an independent marker with prognostic value by combining profiles of lncRNA expression with clinical features of LUAD and somatic mutation profiles. More prospective validation in this study shows that the GILncSig may have significant implications on genomic instability, and have some instructive significance in the customized treatment in LUAD patients.

\section{ACKNOWLEDGEMENTS}

None.

\section{CONFLICT OF INTEREST}

The authors declare no competing interests.

\section{AUTHORS’ CONTRIBUTIONS}

Conceptualization, Y.M., G.Z. and N.L.; data curation, C.G., Y.M. and C.J.; formal analysis, Y.M., J.F., and C.J.; methodology, Y.M. and J.F.; supervision, J.F.; validation, C.G., and Y.M.; writing-original draft, Y.M.; writing-review and editing, C.G., Y.M. and J.F.

\section{ETHICS APPROVAL AND CONSENT TO PARTICIPATE}

Not applicable.

\section{CONSENT FOR PUBLICATION}

All listed authors took part actively in the research and read and approved the manuscript submitted.

\section{DATA AVAILABILITY STATEMENT}

The datasets generated and analyzed during the current study are available in TCGA (http://cancergenome.nih.gov/abouttcga) and GEO (https://www.ncbi.nlm.nih.gov/geo).

\section{ORCID}

Guo-Ping Zhou \(\text{https://orcid.org/0000-0002-7472-9940}\)

\section{REFERENCES}

1. Stahel RA. Adenocarcinoma, a molecular perspective. \textit{Ann Oncol}. 2007;18(Suppl 9):ix147-9.
2. Kadara H, Kabbout M, Wistuba II. Pulmonary adenocarcinoma: a renewed entity in 2011. \textit{Respirology}. 2012;17:50-65.
3. Fan X, Liang Y, Liu Y, Bai Y, Yang C, Xu S. The upregulation of TMPRSS4, partly ascribed to the downregulation of miR-125a-5p, promotes the growth of human lung adenocarcinoma via the NF-κB signaling pathway. \textit{Int J Oncol}. 2018;53:148-158.
4. Zhou X, Hua D, Gao C, Zhang Y, Qiu L, Wang L. Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients. \textit{Oncol Lett}. 2019;18:4153-4159.
5. Gong S, Qu X, Yang S, Zhou S, Li P, Zhang Q. RFC3 induces epithelial-mesenchymal transition in lung adenocarcinoma cells through the Wnt/β-catenin pathway and possesses prognostic value in lung adenocarcinoma. \textit{Int J Mol Med}. 2019;44:2276-2288.
6. Wei JW, Tafe LJ, Liunik YA, Vaikkus LJ, Tomita N, Hassanpour S. Pathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networks. \textit{Sci Rep}. 2019;9:3358.
7. Wang Y, Wang Y, Li K, et al. An interactive network of alternative splicing events with prognostic value in geriatric lung adenocarcinoma via the regulation of splicing factors. \textit{Biosci Rep}. 2020;40(10).
8. Inamura K, Shigematsu Y, Ninomiya H, et al. CSF1R-expressing tumor-associated macrophages, smoking and survival in
lung adenocarcinoma: analyses using quantitative phosphor-integrated dot staining. *Cancers (Basel).* 2018;10.

9. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability—an evolving hallmark of cancer. *Nat Rev Mol Cell Biol.* 2010;11:220-228.

10. Ottini L, Falchetti M, Lupi R, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. *Ann Oncol.* 2006;17(Suppl 7):vii97-vii102.

11. Tam AS, Sihota TS, Milbury KL, Zhang A, Mathew V, Stirling PC. Selective defects in gene expression control genome instability in yeast splicing mutants. *Mol Biol Cell.* 2019;30:191-200.

12. Bao S, Zhao H, Yuan J, et al. Computational identification of mutator-derived IncRNA signatures of genome instability for improving the clinical outcome of cancers: a case study in breast cancer. *Brief Bioinform.* 2020;21:1742-1755.

13. Zeng X, Liu L, Lü L, Zou Q. Prediction of potential disease-associated microRNAs using structural perturbation method. *Bioinformatics.* 2018;34:2425-2432.

14. Zhang X, Zou Q, Rodriguez-Paton A, Zeng X. Meta-path methods for prioritizing candidate disease miRNAs. *IEEE/ACM Trans Comput Biol Bioinform.* 2019;16:283-291.

15. Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. *Nat Struct Mol Biol.* 2015;22:5-7.

16. Koziol MJ, Rinn JL. RNA traffic control of chromatin complexes. *Curr Opin Genet Dev.* 2010;20:142-148.

17. Yuan Y, Shinjo K, Katsushima K. Long non-coding RNAs as an epigenetic regulator in human cancers. *Cancer Sci.* 2017;108:1927-1933.

18. Sanchez CA, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. *Cancer Sci.* 2018;109:2093-2100.

19. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. *Hepatology.* 2006;44:1012-1024.

20. Zhang Y, Shields T, Crenshaw T, Hao Y, Moulton T, Tycko B. Imprinting of human H19: allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. *Am J Hum Genet.* 1993;53:113-124.

21. Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. *Mol Cancer.* 2016;15:43.

22. Prensner JR, Chinnaiyan AM. The emergence of IncRNAs in cancer biology. *Cancer Discov.* 2011;1:391-407.

23. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. *Cancer Cell.* 2016;29:452-463.

24. Liu H. Linking IncRNA to genomic stability. *Sci China Life Sci.* 2016;59:328-329.

25. Munschauer M, Nguyen CT, Sirokman K, et al. The NORAD IncRNA assembles a topoisomerase complex critical for genome stability. *Nature.* 2018;561:132-136.

26. Betts JA, Moradi MM, Al-Ejeh F, et al. Long noncoding RNAs CUPID1 and CUPID2 mediate breast cancer risk at 11q13 by modulating the response to DNA damage. *Am J Hum Genet.* 2017;101:255-266.

27. Polo SE, Blackford AN, Chapman JR, et al. Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. *Mol Cell.* 2012;45:505-516.

28. Sharma V, Khurana S, Kubben N, et al. A BRCA1-interacting IncRNA regulates homologous recombination. *EMBO Rep.* 2015;16:1520-1534.

29. Li J, Han L, Roebuck P, et al. TANRIC: an interactive open platform to explore the function of IncRNAs in cancer. *Cancer Res.* 2015;75:3728-3737.

30. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. *PLoS One.* 2008;3:e1651.

31. Rousseaux S, Debernardi A, Jaquiquia B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. *Sci Transl Med.* 2013;5:186ra66.

32. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS.* 2012;16:284-287.

33. Suzuki R, Kawahara H. UBQLN4 recognizes mislocalized transmembrane domain proteins and targets these to proteasomal degradation. *EMBO Rep.* 2016;17:842-857.

34. Hirayama S, Sugihara M, Morito D, et al. Nuclear export of ubiquitinated proteins via the UBIN-POST system. *Proc Natl Acad Sci USA.* 2018;115:E4199-E4208.

35. Jakowicz RD, Beleggà F, Isensee J, et al. UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors. *Cell.* 2019;176(3):505-519.e22.

36. Jakowicz RD, Reinhardt HC. UBQLN4 promotes non-homologous end joining by repressing DNA end-resection. *Mol Cell Oncol.* 2019;6:1575692.

37. Yu X, Zhang Y. Identification of a long non-coding RNA signature for predicting prognosis and biomarkers in lung adenocarcinoma. *Oncol Lett.* 2020;19:2793-2800.

38. Zeng L, Wang W, Chen Y, et al. A five-long non-coding RNA signature with the ability to predict overall survival of patients with lung adenocarcinoma. *Exp Ther Med.* 2018;16:4852-4864.

39. Shukla S, Evans JR, Malik R, et al. Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. *J Natl Cancer Inst.* 2017;109:djw200.

40. Miao H, Chen D, Li R, et al. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung. *Biosci Rep.* 2021;41(1):BSR20202444.

41. Yasukawa M, Ohbayashi C, Kawaguchi T, et al. Analysis of histological grade in resected lung-invasive adenocarcinoma. *Anticancer Res.* 2019;39:1491-1500.

42. Yang Y, Mao Y, Yang L, et al. Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. *J Thorac Dis.* 2017;9:5267-5277.

43. Deng X, Xiong W, Jiang X, et al. LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. *Cell Death Dis.* 2020;11:945.

44. Dong Y, Yang W, Wang J, et al. MLW-gcForest: a multiweighted gcForest model towards the staging of lung adenocarcinoma based on multi-modal genetic data. *BMC Bioinform.* 2019;20:578.

45. Liang Y, Wang H, Sun Y, et al. miR-198-induced upregulation of Livin may be associated with the prognosis and contribute to the oncogenesis of lung adenocarcinoma. *Oncol Rep.* 2017;38(4):2096-2104.

46. Yin Z, Zhou B, He Q, et al. Association between polymorphisms of Livin may be associated with the prognosis and contribute to the oncogenesis of lung adenocarcinoma. *Oncol Rep.* 2017;38(4):2096-2104.

47. Ramnath VR, Osgood RA. A 36-year-old woman with cough, positive purified protein derivative tuberculin skin test, and cavitary upper lobe consolidation. *Chest.* 2010;137:994-998.
48. Dong Y, Li Y, Jin B, et al. Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. Oncotarget. 2017;8:82244-82255.

49. Kuang M, Shen X, Yuan C, et al. Clinical significance of complex glandular patterns in lung adenocarcinoma: clinicopathologic and molecular study in a large series of cases. Am J Clin Pathol. 2018;150:65-73.

50. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-913.

51. Kronenwett U, Ploner A, Zetterberg A, et al. Genomic instability and prognosis in breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2006;15:1630-1635.

52. Conteduca V, Sansonno D, Ingravallo G, et al. Barrett's esophagus and esophageal cancer: an overview. Int J Oncol. 2012;41:414-424.

53. Gao Y, Kardos J, Yang Y, et al. The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombination DNA Repair and Radiosensitivity in Lung adenocarcinoma cells. Sci Rep. 2018;8:15304.

54. Bouchez C, Kempf E, Tournigand C. MSI Metastatic solid tumors treatment and immunotherapies. Bull Cancer. 2019;106:143-150.

55. Mettu RK, Wan YW, Habermann JK, Ried T, Guo NL. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers. 2010;25:219-228.

56. Ferguson LR, Chen H, Collins AR, et al. Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol. 2015;35(Suppl):S5-S24.

57. Zhang S, Yuan Y, Hao D. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS One. 2014;9:e113169.

58. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-1076.

59. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010;19:R152-R161.

60. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29:742-749.

61. Elguindy MM, Kopp F, Goodarzi M, et al. PUMILIO but not RBMX, binding is required for regulation of genomic stability by noncoding RNA NORAD. Elife. 2019;8:e48625.

62. Ravid O, Shoshani O, Sela M, et al. Relative genomic stability of adipose tissue derived mesenchymal stem cells: analysis of ploidy, H19 long non-coding RNA and p53 activity. Stem Cell Res Ther. 2014;5:139.

63. Hu WL, Jin L, Xu A, et al. GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability. Nat Cell Biol. 2018;20(4):492-502.

64. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181-193.

65. Ock CY, Hwang JE, Keam B, et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017;8:1050.

66. Aoki K, Nakamura H, Suzuki H, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20:66-77.

67. Christen F, Hoyer K, Yoshida K, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133:1140-1151.

68. Zhang M, Zhuang G, Sun X, et al. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol. 2017;12:16.

69. Ripley BM, Gildenberg MS, Washington MT. Control of DNA damage bypass by Ubiquitylation of PCNA. Genes (Basel). 2020;11:138.

70. Syed A, Tainer JA. The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair. Annu Rev Biochem. 2018;87:263-294.

71. Gallina I, Colding C, Henriksen P, et al. Cmr1/WDR76 defines the DNA damage checkpoint and genomic instability and prognosis in breast carcinomas. Nature. 2005;434:907-913.

72. Felipe-Abrio I, Lafuente-Barquero J, García-Rubio ML, Aguilera A. RNA polymerase II contributes to preventing transcription-mediated replication fork stalls. EMBO J. 2015;34:236-250.

73. Mohammed SY, Albassam H, Selim M. Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner. Eur J Nutr. 2020;59:1607-1618.

74. Zhang Y, Saini N, Sheng Z, Lobachev KS. Genome-wide screen reveals replication pathway for quasi-palindrome fragility dependent on homologous recombination. PLoS Genet. 2013;9:e1003979.

75. Hua LL, Mikawa T. Mitotic antipairing of homologous and sex chromosomes via spatial restriction of two haploid sets. Proc Natl Acad Sci USA. 2018;115:E12235-E12244.

76. Christen F, Hoyer K, Yoshida K, et al. Genomic landscape and independent manner. Eur J Nutr. 2020;59:1607-1618.

77. Lai J, Zhou Z, Tang XJ, Gao ZB, Zhou J, Chen SQ. A tumor-based chemotherapeutic attack and prevention through diet and nutrition. Biomed Hub. 2020;5:72-78.

78. Lai J, Zhou Z, Tang XJ, Gao ZB, Zhou J, Chen SQ. A tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma. Int J Mol Sci. 2016;17:739.

79. Chan YA, Hieter P, Stirling PC. Mechanisms of genome instability induced by RNA-processing defects. Trends Genet. 2014;30:245-253.

80. Li X, Payne DT, Ampolus B, et al. Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia. Medchemcomm. 2019;10:1379-1390.

81. Walter L, Canup B, Pujada A, et al. Matrix metalloproteinase 9 (MMP9) limits reactive oxygen species (ROS) accumulation and DNA damage in colitis-associated cancer. Cell Death Dis. 2020;11:767.

82. Borgmann J, Tüttelmann F, Dworniczak B, et al. The human RHOX gene cluster: target genes and functional analysis of gene variants in infertile men. Hum Mol Genet. 2016;25:4898-4910.

83. Wang J, Gao J, Chen Q, et al. LncRNA LINCO11116 contributes to cisplatin resistance in lung adenocarcinoma. Onco Targets Ther. 2020;13:9333-9348.

84. Xiao G, Wang P, Zheng X, Liu D, Sun X. FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14. Cell Cycle. 2019;18:2972-2985.
84. Cho CK, Diamandis EP. Application of proteomics to prenatal screening and diagnosis for aneuploidies. *Clin Chem Lab Med*. 2011;49:33-41.

**SUPPORTING INFORMATION**
Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Guo C-R, Mao Y, Jiang F, Juan C-X, Zhou G-P, Li N. Computational detection of a genome instability-derived IncRNA signature for predicting the clinical outcome of lung adenocarcinoma. *Cancer Med*. 2022;11:864–879. doi:10.1002/cam4.4471